Advertisement

Polymyxin Antibiotics: From Laboratory Bench to Bedside

  • Jian Li
  • Roger L. Nation
  • Keith S. Kaye
Book

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1145)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Tony Velkov, Philip E. Thompson, Mohammad A. K. Azad, Kade D. Roberts, Phillip J. Bergen
    Pages 15-36
  3. Zhifeng Li, Tony Velkov
    Pages 37-54
  4. Jennifer H. Moffatt, Marina Harper, John D. Boyce
    Pages 55-71
  5. Robert W. Milne
    Pages 73-87
  6. Sandrine Marchand, Nicolas Grégoire, William Couet
    Pages 89-103
  7. Winnie Lee, Yiying Cai, Tze-Peng Lim, Jocelyn Teo, Sonja Courtney Chua, Andrea Lay-Hoon Kwa
    Pages 105-116
  8. John Turnidge, Katherine Sei, Johan Mouton
    Pages 117-132
  9. Mical Paul, Oren Zusman, Leonard Leibovici
    Pages 143-153
  10. Dror Marchaim, Donald Kaye, Keith S. Kaye
    Pages 155-179
  11. Jaime Lora-Tamayo, Oscar Murillo, Javier Ariza
    Pages 181-195
  12. Maria Helena Rigatto, Diego R. Falci, Alexandre P. Zavascki
    Pages 197-218
  13. Phillip J. Bergen, Nicholas M. Smith, Tyler B. Bedard, Zackery P. Bulman, Raymond Cha, Brian T. Tsuji
    Pages 251-288
  14. Jason M. Pogue, Vincent H. Tam
    Pages 289-304
  15. Mohammad A. K. Azad, Roger L. Nation, Tony Velkov, Jian Li
    Pages 305-319
  16. Tohru Tani, Tomoharu Shimizu, Masaji Tani, Hisataka Shoji, Yoshihiro Endo
    Pages 321-341
  17. Tony Velkov, Kade D. Roberts
    Pages 343-362
  18. Roger L. Nation
    Pages 363-364
  19. Back Matter
    Pages 365-366

About this book

Introduction

This volume is the first-ever complete treatise on polymyxins and presents the most comprehensive and up-to-date reviews of all major research and clinical topics from chemistry, microbiology, pharmacology, clinical use, to drug discovery. All chapters were written by internationally leading researchers and clinicians in the field.

It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research.

This book provides extensive pharmacological information on polymyxins to infectious diseases clinicians, pharmacists, clinical microbiologists, antimicrobial pharmacologists, and pharmaceutical scientists, and is an essential read for those who aim to develop novel polymyxins and improve their clinical use as a last-line defense against Gram-negative ‘superbugs’.

Keywords

Antibiotic resistance Pharmacokinetics Pharmacodynamics Clinical use Polymyxins to infectious diseases

Editors and affiliations

  • Jian Li
    • 1
  • Roger L. Nation
    • 2
  • Keith S. Kaye
    • 3
  1. 1.Biomedicine Discovery Institute, Infection & Immunity Program and Department of MicrobiologyMonash University, Clayton CampusMelbourneAustralia
  2. 2.Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical SciencesMonash University, Parkville CampusMelbourneAustralia
  3. 3.Division of Infectious DiseasesUniversity of Michigan Medical SchoolAnn ArborUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-030-16373-0
  • Copyright Information Springer Nature Switzerland AG 2019
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-030-16371-6
  • Online ISBN 978-3-030-16373-0
  • Series Print ISSN 0065-2598
  • Series Online ISSN 2214-8019
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology